Duke University Medical Center, DUMC 3309, Durham, NC 27710, USA.
Expert Opin Pharmacother. 2010 May;11(7):1207-14. doi: 10.1517/14656566.2010.482099.
Hydromorphone is a semi-synthetic opioid approved in the USA for the treatment and relief of moderate to severe pain and postoperative pain. However, the compound is short-acting, and there is no extended-release formulation clinically available. A previous hydromorphone extended-release formulation that successfully came to market was subsequently withdrawn on account of safety concerns. Clinical need supports the presence of an extended-release formulation of hydromorphone.
Medline articles showing from a search of 'hydromorphone and OROS' were included in the review. In addition, searches were done relating to published data regarding regulatory affairs dealing with this specific topic. Physicians prescribing information for hydromorphone was also reviewed.
The reader will gain an increased understanding of the use of an extended-release formulation of hydromorphone using the OROS technology and will appreciate that this technology has safety advantages compared with previous extended-release formulations of hydromorphone.
Hydromorphone-OROS is an effective agent for the long-acting control of pain and a welcome addition to other available opioid formulations.
氢吗啡酮是一种半合成阿片类药物,在美国被批准用于治疗和缓解中度至重度疼痛和术后疼痛。然而,该化合物作用时间短,目前临床上没有可延长释放的制剂。先前成功上市的氢吗啡酮延长释放制剂因安全问题而被撤回。临床需求支持氢吗啡酮延长释放制剂的存在。
对“氢吗啡酮和 OROS”的 Medline 文章进行了检索,包括在综述中。此外,还对与处理该特定主题的监管事务相关的已发表数据进行了搜索。还审查了氢吗啡酮的医师处方信息。
读者将更深入地了解使用 OROS 技术的氢吗啡酮延长释放制剂的用途,并认识到与以前的氢吗啡酮延长释放制剂相比,该技术具有安全优势。
氢吗啡酮-OROS 是一种有效控制疼痛的长效药物,是其他可用阿片类药物制剂的有益补充。